| Literature DB >> 33483446 |
Hannah Burke1,2, Anna Freeman3,2, Ahilanandan Dushianthan1,2, Michael Celinski1,2, James Batchelor1,2,4,5, Hang Phan1,5,6, Florina Borca4,6, Christopher Kipps1,2,4,6, Gareth J Thomas7, Saul N Faust1,2,4,6,8, Natasha Sheard2, Sarah Williams2, Paul Fitzpatrick9, Dónal Landers9, Tom Wilkinson1,2.
Abstract
INTRODUCTION: The COVID-19 pandemic caused by SARS-CoV-2 places immense worldwide demand on healthcare services. Earlier identification of patients at risk of severe disease may allow intervention with experimental targeted treatments, mitigating the course of their disease and reducing critical care service demand. METHODS AND ANALYSIS: This prospective observational study of patients tested or treated for SARS-CoV-2, who are under the care of the tertiary University Hospital Southampton NHS Foundation Trust (UHSFT), captured data from admission to discharge; data collection commenced on 7 March 2020. Core demographic and clinical information, as well as results of disease-defining characteristics, was captured and recorded electronically from hospital clinical record systems at the point of testing. Manual data were collected and recorded by the clinical research team for assessments which are not part of the structured electronic healthcare record, for example, symptom onset date. Thereafter, participant records were continuously updated during hospital stay and their follow-up period. Participants aged >16 years were given the opportunity to provide consent for excess clinical sample storage with optional further biological sampling. These anonymised samples were linked to the clinical data in the Real-time Analytics for Clinical Trials platform and were stored within a biorepository at UHSFT. ETHICS AND DISSEMINATION: Ethical approval was obtained from the HRA Specific Review Board (REC 20/HRA/2986) for waiver of informed consent for the database-only cohort; the procedures conform with the Declaration of Helsinki. The study design, protocol and patient-facing documentation for the biobanking arm of the study have been approved by North West Research Ethics Committee (REC 17/NW/0632) as an amendment to the National Institute for Health Research Southampton Clinical Research Facility-managed Southampton Research Biorepository. This study will be published as peer-reviewed articles and presented at conferences, presentations and workshops. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: COVID-19; chronic airways disease; health informatics; protocols & guidelines; respiratory infections; respiratory medicine (see thoracic medicine)
Year: 2021 PMID: 33483446 DOI: 10.1136/bmjopen-2020-043012
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692